These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18707975)

  • 1. Intensive antiplatelet therapy for reduction of ischaemic events.
    Ramaraj R
    Lancet; 2008 Aug; 372(9638):531; author reply 532. PubMed ID: 18707975
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
    Wynn RL
    Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
    Wiviott SD; de Lemos JA
    Am Heart J; 2007 Oct; 154(4):603-6. PubMed ID: 17892976
    [No Abstract]   [Full Text] [Related]  

  • 4. Ischaemia versus bleeding: the art of clinical decision-making.
    Stone GW
    Lancet; 2009 Feb; 373(9665):695-6. PubMed ID: 19249613
    [No Abstract]   [Full Text] [Related]  

  • 5. Approaching an age of reason with antiplatelet therapy.
    Ajani AE; Lefkovits J
    Lancet; 2008 Apr; 371(9621):1315-6. PubMed ID: 18424309
    [No Abstract]   [Full Text] [Related]  

  • 6. Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
    Schömig A
    N Engl J Med; 2009 Sep; 361(11):1108-11. PubMed ID: 19717845
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
    Tapp L; Shantsila E; Lip GY
    Circulation; 2010 Mar; 121(10):1169-71. PubMed ID: 20194888
    [No Abstract]   [Full Text] [Related]  

  • 8. What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
    Testa L; Bhindi R; Van Gaal WJ; Latini RA; Pizzocri S; Lanotte S; Biondi Zoccai GG; Valgimigli M; Laudisa ML; Brambilla N; Banning AP; Bedogni F
    QJM; 2010 Jun; 103(6):367-77. PubMed ID: 20211848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Another view on prasugrel.
    Calatzis A
    Thromb Haemost; 2009 Jan; 101(1):12-3. PubMed ID: 19132183
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of the metabolism of clopidogrel and prasugrel.
    Laizure SC; Parker RB
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1417-24. PubMed ID: 20839914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor in ACS: redefining a new standard of care?
    Stone GW
    Lancet; 2010 Jan; 375(9711):263-5. PubMed ID: 20079529
    [No Abstract]   [Full Text] [Related]  

  • 13. Bedside evaluation of thienopyridine antiplatelet therapy.
    Price MJ
    Circulation; 2009 May; 119(19):2625-32. PubMed ID: 19451364
    [No Abstract]   [Full Text] [Related]  

  • 14. Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
    Solomon S; Vacek JL
    Postgrad Med; 2010 Jan; 122(1):198-200. PubMed ID: 20107305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive antiplatelet therapy for reduction of ischaemic events.
    Marcucci R; Gori AM; Gensini GF; Abbate R
    Lancet; 2008 Aug; 372(9638):531; author reply 532. PubMed ID: 18707976
    [No Abstract]   [Full Text] [Related]  

  • 16. Prasugrel STEMI subgroup analysis.
    Floyd J; Wolfe S
    Lancet; 2009 May; 373(9678):1845-6; author reply 1846-8. PubMed ID: 19482209
    [No Abstract]   [Full Text] [Related]  

  • 17. Prasugrel offers consistent platelet control in appropriate patients requiring treatment.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(2):107, 109. PubMed ID: 21556460
    [No Abstract]   [Full Text] [Related]  

  • 18. [New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome].
    MMW Fortschr Med; 2009 Sep; 151(36):50. PubMed ID: 19813542
    [No Abstract]   [Full Text] [Related]  

  • 19. Prasugrel STEMI subgroup analysis.
    Webster MW; Gladding P
    Lancet; 2009 May; 373(9678):1846; author reply 1846-8. PubMed ID: 19482210
    [No Abstract]   [Full Text] [Related]  

  • 20. Prasugrel.
    Huber K; Yasothan U; Hamad B; Kirkpatrick P
    Nat Rev Drug Discov; 2009 Jun; 8(6):449-50. PubMed ID: 19483707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.